^
Association details:
| Biomarker: | TGFBI promoter hypermethylation |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
69P - TGFBI promoter methylation validation as an epigenetic biomarker for trastuzumab resistance in HER2+ breast cancer patients cohort
Published date:
05/23/2020
Excerpt:
These preliminary results provide a basis for further studies to validate TGFBI hypermethylation as a potential epigenetic monitoring biomarker for trastuzumab resistance in HER2+ BC patients.